Electrically Assisted Movement Therapy
- Conditions
- Cerebrovascular Accident
- Registration Number
- NCT02563886
- Lead Sponsor
- Swiss Federal Institute of Technology
- Brief Summary
The purpose of this study is to determine whether intensive, focused training of the affected upper extremity after stroke results in long-term functional gains in moderately-to-severely paralyzed patients, more than 6 months after their vascular accident. During the course of therapy, user's attempts to move and complete exercises are assisted by neuromuscular electrical stimulation.
- Detailed Description
This pilot study quantifies functional gains induced by the Electrically Assisted Movement Therapy (EAMT), an extension of Constraint-Induced Movement Therapy to moderately-to-severely paralyzed patients in their stable plateau phase of recovery. During EAMT, patients can assist affected upper limb movements through functional electrical stimulation. Initially, patients are divided in two groups. One of the groups receives EAMT, the other receives the best possible physical and occupational therapy. Therapy consists in 40 sessions of 45 minutes twice per day over five weeks, including a one-week therapy break. After 20 sessions, group allocation is crossed-over, and patients don't receive any therapy for one week.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12
- Diagnosis of one, first ever stroke (both ischemic or hemorrhagic) verified by brain imaging (MRI or CT);
- Chronic impairment after stroke (minimum 6 months);
- No contraindications to MRI;
- No contraindications to electrical stimulation;
- Unstable recovery stage (difference between two examinations > 1 FMA-UE point);
- Mild impairment of the upper extremity (FMA-UE >= 21);
- Excessive spasticity of the affected arm (modified Ashworth Scale > 2);
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE), T0 (Before treatment); T1 (3 weeks after start and before treatment crossover); T2 (6 weeks after T0, at the end of treatment); T3 (3 months after treatment); T4 (6 months after treatment) A quantitative measure of motor impairment.
- Secondary Outcome Measures
Name Time Method Wolf Motor Function Test T0 (Before treatment); T1 (3 weeks after start and before treatment crossover); T2 (6 weeks after T0, at the end of treatment); T3 (3 months after treatment); T4 (6 months after treatment) Quality and time of task performance
Motor Activity Log T0 (Before treatment); at 1, 2, 3, 4, 5, 6, 18 and 30 weeks after treatment start Semi-structured interview to assess arm function.
Modified Ashworth scale T0 (Before treatment); T1 (3 weeks after start and before treatment crossover); T2 (6 weeks after T0, at the end of treatment); T3 (3 months after treatment); T4 (6 months after treatment) A quantitative measure of hand and arm spasticity
European stroke scale T0 (Before treatment); T1 (3 weeks after start and before treatment crossover); T2 (6 weeks after T0, at the end of treatment); T3 (3 months after treatment); T4 (6 months after treatment) Overall functional status
Trial Locations
- Locations (1)
Service de Neuropsychologie et neuroréhabilitation - CHUV
🇨🇭Lausanne, VD, Switzerland
Service de Neuropsychologie et neuroréhabilitation - CHUV🇨🇭Lausanne, VD, Switzerland
